Will last year's buybacks morph into more M&A for 2012?

After spending last year focusing on billion-dollar share buybacks to shore up their stock and please investors, European pharma companies may focus more on dealmaking this year, analysts say. Report

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.